The company claims its semaglutide drops, which are applied under the tongue, contain the same active ingredient found in Ozempic and Wegovy and provide the powerful benefits of GLP-1 without injections. EllieMD further touts, under a benefits tab on the drops product page, that the drops offer prescription appetite suppression and are scientifically backed to help users lose weight, adding that the drops can help to lower blood sugar levels and potentially reduce the risk factors associated with conditions like type 2 diabetes, high blood pressure and cardiovascular disease, which are often linked to diabetes. Meanwhile, a recent EllieMD Instagram post boasts about the cardiovascular benefits of its GLP-1 medication, including decreased risk of cardiovascular disease, heart attack and stroke
doi: 10.1038/icb.2010.70 38 YangLChenLLiDXuHChenJMinXet al
doi: 10.1016/j.chom.2013.08.003 37 TsuangMTStoneWSFaraoneSV
GLP-1 is the most extensively studied gut hormone with translational and clinical evidence for its efficacy [10]
Deborah Horn, director of the Center for Obesity Medicine at McGovern Medical School at UTHealth Houston, was quoted in Lilly's official FDA approval announcement
The activation degree of AMPK after four hours of re-feeding differed in both areas